Smithbridge Asset Management Inc. DE Buys 13,388 Shares of Labcorp Holdings Inc. $LH

Posted by Brian Himes on Jun 11th, 2026

Smithbridge Asset Management Inc. DE increased its stake in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 101.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 26,538 shares of the medical research company’s stock after buying an additional 13,388 shares during the period. Smithbridge Asset Management Inc. DE’s holdings in Labcorp were worth $6,658,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. JPL Wealth Management LLC bought a new stake in shares of Labcorp during the 3rd quarter worth about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Labcorp during the 4th quarter worth about $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Labcorp during the 4th quarter worth about $27,000. Eagle Bay Advisors LLC bought a new stake in shares of Labcorp during the 4th quarter worth about $29,000. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after buying an additional 40 shares during the period. Institutional investors own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LH. JPMorgan Chase & Co. lifted their target price on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Piper Sandler lifted their price objective on shares of Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Wall Street Zen upgraded shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $308.00.

Check Out Our Latest Research Report on LH

Insider Activity at Labcorp

In other news, EVP Kathryn W. Kyle sold 762 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the transaction, the executive vice president directly owned 3,813 shares in the company, valued at approximately $1,006,212.57. The trade was a 16.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total transaction of $1,502,313.50. Following the transaction, the chief executive officer owned 107,234 shares of the company’s stock, valued at approximately $27,291,053. This represents a 5.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.84% of the stock is currently owned by insiders.

Labcorp Price Performance

Shares of NYSE:LH opened at $268.52 on Thursday. The firm has a 50 day moving average of $262.84 and a 200-day moving average of $265.78. The stock has a market capitalization of $22.02 billion, a PE ratio of 23.78, a PEG ratio of 1.90 and a beta of 0.90. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a 12 month low of $241.81 and a 12 month high of $293.72.

Labcorp (NYSE:LH – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities research analysts predict that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be given a $0.72 dividend. The ex-dividend date is Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s payout ratio is presently 25.51%.

About Labcorp

(Free Report)

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.